Treating complex CAD indications with sirolimus coated balloon: evidence and performance

Sponsored by Concept Medical

Anchorperson: A. Abizaid

Spokesperson: R. Mehran

Summary

Gain a deeper understanding of how sirolimus coated balloon (SCB) technology is shaping the treatment of complex coronary artery disease (CAD). This EuroPCR 2025 session brings together compelling clinical trial data and real-world case presentations to illustrate the safety, efficacy, and versatility of the MagicTouch SCB in challenging settings. From de-novo lesions to bifurcation strategies, discover how this drug-eluting balloon is becoming a valuable tool in modern PCI, with emerging evidence from the GINGER and HYBRID DEB studies.

Learning Objectives

To know the safety and efficacy of a sirolimus coated balloon with exciting clinical trial evidence
To know the performance of MagicTouch SCB in complex settings and why it is a good choice
To gain an insight into new approaches of using a sirolimus coated balloon for the treatment of bifurcation and de-novo lesions with trial updates

Speaker

D. Jones

Complex case presentation with sirolimus coated balloon